Corrigendum to “Methyl helicterte ameliorates liver fibrosis by regulating miR-21-mediated ERK and TGF-β1/Smads pathways”. (International Immunopharmacology (2019) 66 (41–51), (S1567576918304521), (10.1016/j.intimp.2018.11.006))
Other Scholarly Work
Huang, Q, Zhang, X, Bai, F et al. (2020). Corrigendum to “Methyl helicterte ameliorates liver fibrosis by regulating miR-21-mediated ERK and TGF-β1/Smads pathways”. (International Immunopharmacology (2019) 66 (41–51), (S1567576918304521), (10.1016/j.intimp.2018.11.006))
. INTERNATIONAL IMMUNOPHARMACOLOGY, 79 10.1016/j.intimp.2019.106117
Huang, Q, Zhang, X, Bai, F et al. (2020). Corrigendum to “Methyl helicterte ameliorates liver fibrosis by regulating miR-21-mediated ERK and TGF-β1/Smads pathways”. (International Immunopharmacology (2019) 66 (41–51), (S1567576918304521), (10.1016/j.intimp.2018.11.006))
. INTERNATIONAL IMMUNOPHARMACOLOGY, 79 10.1016/j.intimp.2019.106117
The authors regret that the wrong Fig. 1 (A3 to A5) was published. The correct figures are provided in this corrigendum. The authors would like to apologize for any inconvenience caused. [Figure presented]